In our system, loss or reduction of EphA2 through interaction with YSA-functionalized nanogels may provide an enhanced effect over delivery of EGFR siRNA alone leading to a dual-targeting strategy for chemosensitization of ovarian tumors. This evidence concerns the gene EPHA2 and ovarian neoplasm.